Posts
Mutabilis, the French
biopharmaceutical company, has won a grant for €4 million (about US $5.3
million) in European Union (EU) Framework 7 funding as part of a collaborative
project to develop new antiretroviral drugs to treat HIV.
Mutabilis is coordinating the
research. The purpose of the research is to develop a class of antiretrovirals
that focuses on the interaction between the virus and host.
Researchers involved in the work are
the University College London; the Cancer Research Institute, United Kingdom;
the Academic Medical Center of the University of Amsterdam; the AIDS Units
Clinical Institute of the University of Barcelona; and researchers at the
Institute Cochin, France, and the University Hematology Institute of the Saint
Louis Hospital in Paris, France. The group can receive up to €6 million (about
US $7.9 million) in funding over a three-year time frame.
The Friends of AIDS Foundation is
dedicated to enhancing the quality of life for HIV positive individuals and
empowering people to make healthy choices to prevent the spread of the HIV
virus. To learn more about The Friends of AIDS Foundation, please visit: http://www.friendsofaids.org.
TOGETHER WE REMAIN STRONG!
